Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN UFH versus XARELTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN UFH versus XARELTO.
Heparin (UFH) vs XARELTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Direct factor Xa inhibitor that selectively blocks the active site of factor Xa, inhibiting thrombin generation and thrombus formation.
Intravenous: Initial bolus of 80 units/kg (or 5000 units) followed by continuous infusion of 18 units/kg/h (or 1300 units/h), adjusted to maintain aPTT 1.5-2.5 times control. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
15 mg orally twice daily for 21 days, then 20 mg orally once daily; for atrial fibrillation: 20 mg orally once daily with food; for VTE prophylaxis in hip or knee replacement: 10 mg orally once daily.
None Documented
None Documented
0.5–2 hours (dose-dependent; at therapeutic doses, ~1–2 h; with higher doses, up to 2.5 h). Clinical context: shorter half-life in pulmonary embolism; prolonged in hepatic or renal impairment.
Terminal elimination half-life: 5–9 hours in young adults, 11–13 hours in elderly (≥65 years). Clinical context: Twice-daily dosing due to relatively short half-life; renal impairment prolongs half-life (up to 15 hours in severe impairment).
Primarily cleared via reticuloendothelial system and metabolism; renal excretion of unchanged drug is minimal (<5%).
Renal (36% as unchanged drug, 30% as inactive metabolites), fecal/biliary (33% as unchanged drug via hepatobiliary route). Total clearance is 10 L/h.
Category A/B
Category C
Anticoagulant
Anticoagulant